Oxford BioMedica (LSE:OXB) EV-to-EBIT : -1.91 (As of May. 17, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Oxford BioMedica's Enterprise Value is £338.74 Mil. Oxford BioMedica's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-177.33 Mil. Therefore, Oxford BioMedica's EV-to-EBIT for today is -1.91.

The historical rank and industry rank for Oxford BioMedica's EV-to-EBIT or its related term are showing as below:

LSE:OXB' s EV-to-EBIT Range Over the Past 10 Years
Min: -275.34 Med: -10.54 Max: 47.36
Current: -1.91

During the past 13 years, the highest EV-to-EBIT of Oxford BioMedica was 47.36. The lowest was -275.34. And the median was -10.54.

LSE:OXB's EV-to-EBIT is ranked worse than
100% of 431 companies
in the Biotechnology industry
Industry Median: 10 vs LSE:OXB: -1.91

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Oxford BioMedica's Enterprise Value for the quarter that ended in Dec. 2023 was £224.54 Mil. Oxford BioMedica's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-177.33 Mil. Oxford BioMedica's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -78.97%.

Oxford BioMedica EV-to-EBIT Historical Data

The historical data trend for Oxford BioMedica's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica EV-to-EBIT Chart

Oxford BioMedica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-31.64

-143.95

46.24

-11.57

-1.27

Oxford BioMedica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															46.24	-	-11.57	-	-1.27

Competitive Comparison of Oxford BioMedica's EV-to-EBIT

For the Biotechnology subindustry, Oxford BioMedica's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioMedica's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's EV-to-EBIT falls into.

Oxford BioMedica EV-to-EBIT Calculation

Oxford BioMedica's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	338.743	/	-177.328
	=	-1.91

Oxford BioMedica's current Enterprise Value is £338.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-177.33 Mil.

Oxford BioMedica (LSE:OXB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Oxford BioMedica's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-177.328	/	224.53968
	=	-78.97 %

Oxford BioMedica's Enterprise Value for the quarter that ended in Dec. 2023 was £224.54 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-177.33 Mil.

Oxford BioMedica EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioMedica (LSE:OXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

OXBDF:USA OXBl:UK OXO:Germany

Address

Windrush Court, Transport Way, Oxford, GBR, OX4 6LT

Website

https://www.oxb.com

Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines